Journal of Breast Cancer,
Journal Year:
2023,
Volume and Issue:
26(3), P. 207 - 207
Published: Jan. 1, 2023
This
article
provides
an
annual
update
of
Korean
breast
cancer
statistics,
including
the
incidence,
tumor
stage,
type
surgical
treatment,
and
mortality.
The
data
was
collected
from
Breast
Cancer
Society
registry
system
Central
Registry.
In
2019,
29,729
women
were
newly
diagnosed
with
cancer.
has
continued
to
increase
in
incidence
since
2002
been
most
common
2019.
Of
cases
24,820
(83.5%)
invasive
carcinomas,
4,909
(16.5%)
carcinoma
situ.
median
age
52.8
years,
commonly
group
40-49
years.
number
patients
who
have
undergone
conserving
surgery
2016,
68.6%
undergoing
early-stage
continues
increase,
stage
0
or
I
accounting
for
61.6%
cases.
subtype
is
hormone
receptor-positive
human
epidermal
growth
factor
receptor
2-negative
(63.1%).
5-year
relative
survival
rate
2015
2019
93.6%,
14.3%
compared
that
1993
1995.
report
improves
our
understanding
characteristics
South
Korea.
Biological Procedures Online,
Journal Year:
2013,
Volume and Issue:
15(1)
Published: Feb. 13, 2013
The
wide
application
of
next-generation
sequencing
(NGS),
mainly
through
whole
genome,
exome
and
transcriptome
sequencing,
provides
a
high-resolution
global
view
the
cancer
genome.
Coupled
with
powerful
bioinformatics
tools,
NGS
promises
to
revolutionize
research,
diagnosis
therapy.
In
this
paper,
we
review
recent
advances
in
NGS-based
genomic
research
as
well
clinical
application,
summarize
current
integrative
oncogenomic
projects,
resources
computational
algorithms,
discuss
challenge
future
directions
sequencing.
Human Vaccines & Immunotherapeutics,
Journal Year:
2013,
Volume and Issue:
10(1), P. 52 - 63
Published: Sept. 24, 2013
The
high
mortality
rate
associated
with
cancer
and
its
resistance
to
conventional
treatments
such
as
radiation
chemotherapy
has
led
the
investigation
of
a
variety
anti-cancer
immunotherapies.
development
novel
immunotherapies
been
bolstered
by
discovery
tumor-associated
antigens
(TAAs),
through
gene
sequencing
proteomics.
One
immunotherapy
employs
established
allogeneic
human
cell
lines
induce
antitumor
immunity
in
patients
TAA
presentation.
Allogeneic
are
desirable
clinical
setting
due
their
ease
production
availability.
This
review
aims
summarize
trials
tumor
various
types.
To
date,
have
shown
limited
success
potentially
extensive
degrees
inter-
intra-tumoral
heterogeneity
found
among
patients.
However,
these
results
provide
guidance
for
rational
design
creation
more
effective
use
monotherapies
or
combination
other
therapies.
Journal of Breast Cancer,
Journal Year:
2023,
Volume and Issue:
26(3), P. 207 - 207
Published: Jan. 1, 2023
This
article
provides
an
annual
update
of
Korean
breast
cancer
statistics,
including
the
incidence,
tumor
stage,
type
surgical
treatment,
and
mortality.
The
data
was
collected
from
Breast
Cancer
Society
registry
system
Central
Registry.
In
2019,
29,729
women
were
newly
diagnosed
with
cancer.
has
continued
to
increase
in
incidence
since
2002
been
most
common
2019.
Of
cases
24,820
(83.5%)
invasive
carcinomas,
4,909
(16.5%)
carcinoma
situ.
median
age
52.8
years,
commonly
group
40-49
years.
number
patients
who
have
undergone
conserving
surgery
2016,
68.6%
undergoing
early-stage
continues
increase,
stage
0
or
I
accounting
for
61.6%
cases.
subtype
is
hormone
receptor-positive
human
epidermal
growth
factor
receptor
2-negative
(63.1%).
5-year
relative
survival
rate
2015
2019
93.6%,
14.3%
compared
that
1993
1995.
report
improves
our
understanding
characteristics
South
Korea.
